Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice Mariottini

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
Handbook of Clinical Neurology|August 7, 2024
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocolsAlice Mariottini, Riccardo Saccardi
Frontiers in Immunology|December 20, 2021
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple SclerosisRoberta Amoriello, Alice Mariottini, Clara Ballerini
Journal of Clinical Medicine|July 27, 2022
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple SclerosisLuca Massacesi, Alice Mariottini, Ferdinando Nicoletti
Multiple Sclerosis and Related Disorders|August 12, 2023
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?Alice Mariottini, Paolo A Muraro, Riccardo Saccardi
Handbook of Clinical Neurology|August 7, 2024
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosisAlice Mariottini, Maria Teresa Cencioni, Paolo Antonio Muraro
Frontiers in Immunology|September 29, 2022
Antibody-mediated cell depletion therapies in multiple sclerosisAlice Mariottini, Paolo A Muraro, Jan D Lünemann
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 14, 2020
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current StatusAlice Mariottini, Eleonora De Matteis, Paolo A Muraro
Multiple Sclerosis and Related Disorders|September 3, 2024
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE studyAlice Mariottini, Fabrizia Mealli, Alessandra Mattei, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2024
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE studyFabrizia Mealli, Alessandra Mattei, Alice Mariottini, et al.
Microorganisms|October 26, 2024
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis-The Elephant Is (Still) in the RoomAlice Mariottini, Antonio Lotti, Valentina Damato, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
Handbook of Clinical Neurology|August 7, 2024
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocolsAlice Mariottini, Riccardo Saccardi
Frontiers in Immunology|December 20, 2021
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple SclerosisRoberta Amoriello, Alice Mariottini, Clara Ballerini
Journal of Clinical Medicine|July 27, 2022
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple SclerosisLuca Massacesi, Alice Mariottini, Ferdinando Nicoletti
Multiple Sclerosis and Related Disorders|August 12, 2023
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis?Alice Mariottini, Paolo A Muraro, Riccardo Saccardi
Handbook of Clinical Neurology|August 7, 2024
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosisAlice Mariottini, Maria Teresa Cencioni, Paolo Antonio Muraro
Frontiers in Immunology|September 29, 2022
Antibody-mediated cell depletion therapies in multiple sclerosisAlice Mariottini, Paolo A Muraro, Jan D Lünemann
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|March 14, 2020
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current StatusAlice Mariottini, Eleonora De Matteis, Paolo A Muraro
Multiple Sclerosis and Related Disorders|September 3, 2024
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: A post-hoc analysis of the REFINE studyAlice Mariottini, Fabrizia Mealli, Alessandra Mattei, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2024
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE studyFabrizia Mealli, Alessandra Mattei, Alice Mariottini, et al.
Microorganisms|October 26, 2024
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis-The Elephant Is (Still) in the RoomAlice Mariottini, Antonio Lotti, Valentina Damato, et al.
Pageof 5